Ahmed Z. Obeidat

Sep 6, 2024 | journals.sagepub.com | Ahmed Z. Obeidat

Get full access to this articleView all access and purchase options for this article. Data availability statementData sharing not applicable to this article as no datasets were generated or analyzed during this study. References1. Dalla Costa G, Leocani L, Pisa M, et al. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. Mult Scler J. Epub ahead of print 14 June 2024. 2. Foley JF, Defer G, Ryerson LZ, et al.

Mar 4, 2024 | neurologylive.com | Mark Freedman |Tanuja Chitnis |Ahmed Z. Obeidat

March 4, 2024OpinionVideoThis program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC. Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss future directions in MS amid increasing advances in the field. Experts discuss the approach to explaining NFL results to patients and their families.

Jan 29, 2024 | neurologylive.com | Mark Freedman |Tanuja Chitnis |Ahmed Z. Obeidat

Experts discuss the challenges with routine MRI usage and the potential role of serum biomarkers like neurofilament light (NFL) as an alternative. They address the correlation between serum NFL and MRI findings. Tanuja Chitnis, MD, explains that NFL levels are elevated during acute gadolinium-enhancing lesions, with variations based on lesion size and number. Larger lesions and multiple lesions correlate with higher NFL levels.

Jan 22, 2024 | neurologylive.com | Mark Freedman |Tanuja Chitnis |Ahmed Z. Obeidat

January 22, 2024OpinionVideoThis program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC. Tanuja Chitnis, MD, discusses the use of ultra-sensitive assays to determine protein levels in the blood, which may aid in the diagnosis of MS. Mark Freedman, MD, MSc, addresses the historical measurement of neurofilament light chain (NFL) in spinal fluid due to higher levels, necessitating lumbar punctures.